rBC2LCN lectin as a potential probe of early‐stage HER2‐positive breast carcinoma
The recombinant N‐terminal domain of BC2L‐C lectin (rBC2LCN) is useful for detecting not only human pluripotent stem cells but also some cancers. However, the cancer types and stages that can be detected by rBC2LCN remain unclear. In this study, we identified the human breast carcinoma subtypes and...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-06-01
|
| Series: | FEBS Open Bio |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/2211-5463.12852 |
| _version_ | 1828445978046234624 |
|---|---|
| author | Shuuji Mawaribuchi Yoshikazu Haramoto Hiroaki Tateno Yasuko Onuma Yasuhiko Aiki Yuzuru Ito |
| author_facet | Shuuji Mawaribuchi Yoshikazu Haramoto Hiroaki Tateno Yasuko Onuma Yasuhiko Aiki Yuzuru Ito |
| author_sort | Shuuji Mawaribuchi |
| collection | DOAJ |
| description | The recombinant N‐terminal domain of BC2L‐C lectin (rBC2LCN) is useful for detecting not only human pluripotent stem cells but also some cancers. However, the cancer types and stages that can be detected by rBC2LCN remain unclear. In this study, we identified the human breast carcinoma subtypes and stages that can be detected by rBC2LCN. Compared with rBC2LCN‐negative breast carcinoma cell lines, the rBC2LCN‐positive cells expressed higher levels of human epidermal growth factor receptor 2 (HER2) and epithelial marker genes. Importantly, rBC2LCN histochemical staining of human breast carcinoma tissues demonstrated the utility of rBC2LCN in detecting breast carcinoma types that express HER2 and have not spread much in the early phase of growth. We conclude that rBC2LCN may have potential as a detection probe and a drug delivery vehicle to identify and treat early‐stage HER2‐positive breast carcinoma. |
| first_indexed | 2024-12-10T22:05:32Z |
| format | Article |
| id | doaj.art-06fc8d4b85124e1da1032dee96e00042 |
| institution | Directory Open Access Journal |
| issn | 2211-5463 |
| language | English |
| last_indexed | 2024-12-10T22:05:32Z |
| publishDate | 2020-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | FEBS Open Bio |
| spelling | doaj.art-06fc8d4b85124e1da1032dee96e000422022-12-22T01:31:45ZengWileyFEBS Open Bio2211-54632020-06-011061056106410.1002/2211-5463.12852rBC2LCN lectin as a potential probe of early‐stage HER2‐positive breast carcinomaShuuji Mawaribuchi0Yoshikazu Haramoto1Hiroaki Tateno2Yasuko Onuma3Yasuhiko Aiki4Yuzuru Ito5Biotechnology Research Institute for Drug Discovery National Institute of Advanced Industrial Science and Technology (AIST) Tsukuba JapanBiotechnology Research Institute for Drug Discovery National Institute of Advanced Industrial Science and Technology (AIST) Tsukuba JapanBiotechnology Research Institute for Drug Discovery National Institute of Advanced Industrial Science and Technology (AIST) Tsukuba JapanBiotechnology Research Institute for Drug Discovery National Institute of Advanced Industrial Science and Technology (AIST) Tsukuba JapanBiotechnology Research Institute for Drug Discovery National Institute of Advanced Industrial Science and Technology (AIST) Tsukuba JapanBiotechnology Research Institute for Drug Discovery National Institute of Advanced Industrial Science and Technology (AIST) Tsukuba JapanThe recombinant N‐terminal domain of BC2L‐C lectin (rBC2LCN) is useful for detecting not only human pluripotent stem cells but also some cancers. However, the cancer types and stages that can be detected by rBC2LCN remain unclear. In this study, we identified the human breast carcinoma subtypes and stages that can be detected by rBC2LCN. Compared with rBC2LCN‐negative breast carcinoma cell lines, the rBC2LCN‐positive cells expressed higher levels of human epidermal growth factor receptor 2 (HER2) and epithelial marker genes. Importantly, rBC2LCN histochemical staining of human breast carcinoma tissues demonstrated the utility of rBC2LCN in detecting breast carcinoma types that express HER2 and have not spread much in the early phase of growth. We conclude that rBC2LCN may have potential as a detection probe and a drug delivery vehicle to identify and treat early‐stage HER2‐positive breast carcinoma.https://doi.org/10.1002/2211-5463.12852breast carcinomaepithelial‐to‐mesenchymal transitionHER2lectinrBC2LCN |
| spellingShingle | Shuuji Mawaribuchi Yoshikazu Haramoto Hiroaki Tateno Yasuko Onuma Yasuhiko Aiki Yuzuru Ito rBC2LCN lectin as a potential probe of early‐stage HER2‐positive breast carcinoma FEBS Open Bio breast carcinoma epithelial‐to‐mesenchymal transition HER2 lectin rBC2LCN |
| title | rBC2LCN lectin as a potential probe of early‐stage HER2‐positive breast carcinoma |
| title_full | rBC2LCN lectin as a potential probe of early‐stage HER2‐positive breast carcinoma |
| title_fullStr | rBC2LCN lectin as a potential probe of early‐stage HER2‐positive breast carcinoma |
| title_full_unstemmed | rBC2LCN lectin as a potential probe of early‐stage HER2‐positive breast carcinoma |
| title_short | rBC2LCN lectin as a potential probe of early‐stage HER2‐positive breast carcinoma |
| title_sort | rbc2lcn lectin as a potential probe of early stage her2 positive breast carcinoma |
| topic | breast carcinoma epithelial‐to‐mesenchymal transition HER2 lectin rBC2LCN |
| url | https://doi.org/10.1002/2211-5463.12852 |
| work_keys_str_mv | AT shuujimawaribuchi rbc2lcnlectinasapotentialprobeofearlystageher2positivebreastcarcinoma AT yoshikazuharamoto rbc2lcnlectinasapotentialprobeofearlystageher2positivebreastcarcinoma AT hiroakitateno rbc2lcnlectinasapotentialprobeofearlystageher2positivebreastcarcinoma AT yasukoonuma rbc2lcnlectinasapotentialprobeofearlystageher2positivebreastcarcinoma AT yasuhikoaiki rbc2lcnlectinasapotentialprobeofearlystageher2positivebreastcarcinoma AT yuzuruito rbc2lcnlectinasapotentialprobeofearlystageher2positivebreastcarcinoma |